Skye Bioscience 관리

관리 기준 확인 1/4

Skye Bioscience CEO는 Punit Dhillon, Aug2020 에 임명되었습니다 의 임기는 4.25 년입니다. 총 연간 보상은 $ 1.81M, 24.9% 로 구성됩니다. 24.9% 급여 및 75.1% 보너스(회사 주식 및 옵션 포함). 는 $ 1.44M 가치에 해당하는 회사 주식의 1.12% 직접 소유합니다. 1.44M. 경영진과 이사회의 평균 재임 기간은 각각 2.5 년과 0.7 년입니다.

주요 정보

Punit Dhillon

최고 경영자

US$1.8m

총 보상

CEO 급여 비율	24.9%
CEO 임기	4.3yrs
CEO 소유권	1.1%
경영진 평균 재임 기간	2.5yrs
이사회 평균 재임 기간	less than a year

최근 관리 업데이트

Recent updates

Skye: Moving Weight Loss Drugs To The Next Level

Sep 04

Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

Aug 11

CEO 보상 분석

Punit Dhillon 의 보수는 Skye Bioscience 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$21m
Jun 30 2024	n/a	n/a	-US$42m
Mar 31 2024	n/a	n/a	-US$37m
Dec 31 2023	US$2m	US$450k	-US$38m
Sep 30 2023	n/a	n/a	-US$43m
Jun 30 2023	n/a	n/a	-US$21m
Mar 31 2023	n/a	n/a	-US$22m
Dec 31 2022	US$668k	US$433k	-US$19m
Sep 30 2022	n/a	n/a	-US$12m
Jun 30 2022	n/a	n/a	-US$11m
Mar 31 2022	n/a	n/a	-US$9m
Dec 31 2021	US$900k	US$400k	-US$9m
Sep 30 2021	n/a	n/a	-US$8m
Jun 30 2021	n/a	n/a	-US$7m
Mar 31 2021	n/a	n/a	-US$6m
Dec 31 2020	US$615k	US$160k	-US$7m
Sep 30 2020	n/a	n/a	-US$207k
Jun 30 2020	n/a	n/a	-US$4m
Mar 31 2020	n/a	n/a	US$13m
Dec 31 2019	US$65k	n/a	US$1m
Sep 30 2019	n/a	n/a	-US$10m
Jun 30 2019	n/a	n/a	-US$7m
Mar 31 2019	n/a	n/a	-US$26m
Dec 31 2018	US$82k	n/a	-US$19m

보상 대 시장: Punit 의 총 보상 ($USD 1.81M )은 US 시장( $USD 642.87K ).

보상과 수익: 회사가 수익성이 없는 동안 Punit 의 보상이 증가했습니다.

CEO

Punit Dhillon (44 yo)

4.3yrs

테뉴어

US$1,807,338

보상

Mr. Punit S. Dhillon, BA, has been Chief Executive Officer of Skye Bioscience, Inc. since August 10, 2020. Mr. Dhillon serves as Chair of Skye Bioscience, Inc. until October 25, 2024. He served as Principa...

리더십 팀

이름	위치	테뉴어	보상	소유권
Punit Dhillon	President	4.3yrs	US$1.81m	1.12% $ 1.4m
Kaitlyn Arsenault	Chief Financial Officer	3.1yrs	US$1.27m	0.55% $ 708.6k
Christopher Twitty	Chief Scientific Officer	1.9yrs	데이터 없음	데이터 없음
Tu Diep	Chief Development Officer	no data	데이터 없음	0.27% $ 350.4k
Puneet Arora	Chief Medical Officer	less than a year	데이터 없음	데이터 없음

2.5yrs

평균 재임 기간

43.5yo

평균 연령

경험이 풍부한 관리: SKYE 의 관리팀은 경험 ( 2.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Punit Dhillon	President	6.8yrs	US$1.81m	1.12% $ 1.4m
Paul Grayson	Independent Chairman of the Board	1.3yrs	US$1.25m	0.86% $ 1.1m
Andrew Schwab	Director	1.3yrs	US$74.08k	0% $ 0
Louis Aronne	Member of Clinical & Scientific Advisory Board	less than a year	데이터 없음	데이터 없음
Annalisa Lisa Jenkins	Independent Director	less than a year	데이터 없음	0% $ 0
Karen Smith	Director	less than a year	데이터 없음	0% $ 0
Deborah Charych	Independent Director	1.8yrs	US$102.28k	0% $ 0
Rekha Kumar	Member of Clinical & Scientific Advisory Board	less than a year	데이터 없음	데이터 없음
Lee Kaplan	Member of Clinical & Scientific Advisory Board	less than a year	데이터 없음	데이터 없음
Beverly Tchang	Member of Clinical & Scientific Advisory Board	less than a year	데이터 없음	데이터 없음
Marcus Goncalves	Member of Clinical & Scientific Advisory Board	less than a year	데이터 없음	데이터 없음

0.7yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: SKYE 의 이사회는 경험(평균 재직 기간 0.7 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Skye Bioscience 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Skye Bioscience Names Paul Grayson as Chairman of the Board

Skye Bioscience, Inc. Appoints Puneet S. Arora as Chief Medical Officer

Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab

Skye Bioscience, Inc. Appoints Dr. Karen Smith to Board of Directors, Effective August 1, 2024

High number of new directors

Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors

Recent updates

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated Cb1 Inhibitor

Skye Bioscience Demonstrates Prominent Role of Peripheral Cb1 Inhibition and Achieves Significant Weight Loss with Novel Cb1-Inhibiting Antibody, Nimacimab, in Preclinical Model

Skye Bioscience, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Skye Bioscience Names Paul Grayson as Chairman of the Board

Skye Bioscience, Inc.(NasdaqGM:SKYE) dropped from NASDAQ Transportation Index

Skye Bioscience, Inc.(NasdaqGM:SKYE) dropped from NASDAQ Transportation Index

Skye: Moving Weight Loss Drugs To The Next Level

Skye Bioscience, Inc. Appoints Puneet S. Arora as Chief Medical Officer

Skye Bioscience, Inc. Launches Phase 2 Cbeyond Clinical Trial of Its Differentiated Cb1 Inhibitor, Nimacimab, in Patients with Obesity

Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

Skye Bioscience, Inc. Announces Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints

Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab

Skye Bioscience, Inc. Appoints Dr. Karen Smith to Board of Directors, Effective August 1, 2024

Skye Bioscience, Inc. Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program

Skye Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Revenue and earnings growth

High number of new directors

Skye Bioscience, Inc. announced that it has received $40 million in funding from 5AM Venture Management, LLC

Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors

Skye Bioscience Completes Enrollment of Phase 2A Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension

Skye Bioscience, Inc. announced that it has received $49.99101 million in funding

Skye Bioscience, Inc. announced that it expects to receive $50.249992 million in funding

Skye Bioscience, Inc. Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab

Skye Bioscience, Inc. Announces Board Appointments

New major risk - Share price stability

Skye Bioscience, Inc. Appoints Deborah Charych to Board of Directors

Skye Bioscience Announces First-in-Human Phase 1 Trial of Proprietary Cannabinoid Derivative and Nanoemulsion Formulation Designed to Potentially Treat Glaucoma

Skye Bioscience, Inc. Appoints Rai as Member of the Nominating and Corporate Governance Committee of the Board

Skye Bioscience, Inc. Appoints Chris Twitty as Chief Scientific Officer

Skye Bioscience, Inc. (OTCPK:SKYE) completed the acquisition of Emerald Health Therapeutics, Inc. (CNSX:EMH) from Emerald Health Sciences Inc. and others.

Skye Bioscience, Inc. Completes Drug Production for Phase 1 Clinical Study

Skye Bioscience, Inc. Updates Phase 1 Timeline

Skye Bioscience, Inc. Announces Resignation of Jim Heppell as A Member of Board of Directors, Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee

Skye Bioscience, Inc. (OTCPK:SKYE) entered into a definitive agreement to acquire Emerald Health Therapeutics, Inc. (CNSX:EMH) for CAD 21.7 million.

Skye Bioscience, Inc. Reports Positive Results for SBI-100 in GLP Toxicology Study

Skye Bioscience, Inc. Reports Potential Neuroprotective Benefit of SBI-100 in Preclinical Glaucoma Model

Skye Bioscience Announces THCVHS Late-Breaking Preclinical Abstracts Selected by American Association of Pharmaceutical Scientists Meeting PharmSci 360

Skye Bioscience’s THCVHS Demonstrates Superior Therapeutic Benefit Compared to Glaucoma Standard of Care, Both as Combination and Single Agent, in Preclinical Study

Skye Bioscience, Inc. Announces Board Appointments

Emerald Bioscience Inc., Annual General Meeting, Jan 28, 2021

Emerald Bioscience Inc. Provides an Update on Progress across its Product Pipeline, including adjusted clinical milestones

Emerald Bioscience Inc. Announces Changes in Principal Financial Officer

Emerald Bioscience Inc. Announces Executive Changes

Emerald Bioscience Inc. has completed a Composite Units Offering in the amount of $6.939667 million.

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령